Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 12/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.61 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.61 |
| ▸ | ESRRG | P62508 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431498 | 0.88 | MLYCD (0.79) | MLYCDNR1H3NR1H2ESRRG | |
| SCHEMBL2945131 | 0.86 | MLYCD (1.00) | MLYCDNR1H3NR1H2RORC | |
| SCHEMBL14540969 | 0.84 | MLYCD (0.72) | MLYCDNR1H3NR1H2ESRRG | |
| SCHEMBL12133560 | 0.81 | MLYCD (0.72) | MLYCDESRRG | |
| SCHEMBL257847 | 0.79 | MLYCD (0.69) | MLYCDESRRG | |
| SCHEMBL27891608 | 0.76 | MLYCD (0.65) | MLYCDESRRG | |
| SCHEMBL1379430 | 0.76 | NR1H2 (1.00) | MLYCDNR1H3NR1H2RORC | |
| SCHEMBL177498 | 0.75 | MLYCD (0.64) | MLYCDESRRG | |
| SCHEMBL13181408 | 0.75 | MLYCD (0.64) | MLYCD | |
| SCHEMBL3230674 | 0.75 | MLYCD (0.78) | MLYCDNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7385063-B2 | Method for preparing imidazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7385063-B2 | Method for preparing imidazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7385063-B2 | Method for preparing imidazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1353662-B1 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | MLYCD 6/4885NR1H3 1227/4885NR1H2 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.